Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

featured-image

Veracyte, Inc. ( NASDAQ: VCYT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Shayla Gorman - Senior Director, Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Andrew Brackmann - William Blair Lu Li - UBS Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank Thomas DeBourcy - Nephron Research Mike Matson - Needham Puneet Souda - Leerink Partners Operator Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2024 Conference Call.

[Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Shayla Gorman, Senior Director of Investor Relations. Sheila, you have the floor.



Shayla Gorman Good afternoon, everyone, and thank you for joining us today for a discussion of our third quarter 2024 financial results. With me today are Marc Stapley, Veracyte's Chief Executive Officer; and Rebecca Chambers, our Chief Financial Officer. Veracyte issued a press release earlier this afternoon detailing our third quarter 2024 financial results.

This release and a business and financial presentation are available in the Investor Relations section of our website at veracyte.com. Before we begin, I'd like to remind you that various statements we make during this call will include forward-looking statements as defined under applicable securities laws.

Forward-looking statements are subject to risks and uncertainties and the company can give no assurance they will prove to be correct. Additionally, we are not under any obligation to provide further updates on our business trends or our performance during the quarter. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Veracyte filed with the Securities and Exchange Commission, including Veracyte's most.